CytoMed Therapeutics is a Singapore-based biopharmaceutical company developing cell-based immunotherapies for cancer and degenerative diseases, operating through subsidiaries in Singapore and Malaysia. The company generates revenue from private cord blood banking services, research services and consultancy, and government grants, while investing substantially in research and development of immune cell and pluripotent stem cell therapies. Its customers include healthcare institutions and research organizations, and the company holds intellectual property licenses for proprietary technology platforms in cell-based therapeutics as it pursues regulatory approvals for clinical applications.